Author of

• 20167

  +

  P2.03 - Chemotherapy/Targeted Therapy (ID 704)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Chemotherapy/Targeted Therapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 23321

    +

    P2.03-050 - The Efficacy of EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer Harboring G719X Mutation (ID 9927)

    09:30 - 09:30  |  Author(s): X. Zhang
    • Abstract
    • Slides

    Background:
    Few uncommon EGFR mutations existed in NSCLC patients, such as G719X mutation on 18 exon. The best treatment option for G719X mutation is unclear, and it is usually excluded from clinical trials using EGFR TKI therapy. Here we studied the clinical data of patients harboring G719X mutation in real world and their sensitivity to EGFR TKIs.
    
    Method:
    Between January 2011 and December 2016, we retrospectively collected the clinical data of stage IIIB/IV NSCLC patients harboring G719X mutation at Peking Union Medical College Hospital.
    
    Result:
    A total of 830 NSCLC patients were found to harbor common sensitive EGFR mutations ( 417 patients harbored 19 exon deletion，413 patients harbored 21 L858 mutation, respectively), while 27 (27/857, 3.15%) patients harbored G719X mutation on 18 Exon, using amplification refractory mutation system (ARMs). 19 (19/27, 70.4%) patients with G719X mutation were treated with EGFR TKIs, 11 (57.9%) with Gefitinib, 5 (26.3%) with Icotinib, and 3 (15.8%) with Erlotinib, respectively. The median age was 58.3 years ( range from 30 to 79 years). There were 11(57.9%) females, and 6 (31.6%) patients with history of heavy smoking. 3 (15.8%) patients had baseline central nervous systemic metastasis. 11(57.9%) patients had unique G719x mutation, while 8 patient had compound mutations (5 patients had G719+20s768I, 2 patients had G719+L861Q, and 1 patient had G719+19del). 9 (47.4%) patients gained PR, 7 (36.8%) patients gained SD, and 3 (15.8%) achieved PD, the ORR was 47.4%, and the DCR was 84.2%. The median PFS was 8.8 months (95% CI: 0.932-16.67). The median PFS of first-line TKI therapy was longer than second-line TKI therapy (10.8months vs. 4.0months respectively), but it didn’t got statistical significance (p=0.226). The median OS was 15.3 months (95%CI: 12.3-18.3), with 6 patients still alive. There were no intolerant adverse effect associating with EGFR TKIs.
    
    Conclusion:
    These results suggest that EGFR TKI therapy is effective in patients with G719X mutations. EGFR TKI could be a treatment choice better than chemotherapy for patients harboring G719X mutation.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.